ApoE Cascade Hypothesis in the pathogenesis of Alzheimer's disease and related dementias
- PMID: 35298921
- PMCID: PMC9035117
- DOI: 10.1016/j.neuron.2022.03.004
ApoE Cascade Hypothesis in the pathogenesis of Alzheimer's disease and related dementias
Abstract
The ε4 allele of the apolipoprotein E gene (APOE4) is a strong genetic risk factor for Alzheimer's disease (AD) and several other neurodegenerative conditions, including Lewy body dementia (LBD). The three APOE alleles encode protein isoforms that differ from one another only at amino acid positions 112 and 158: apoE2 (C112, C158), apoE3 (C112, R158), and apoE4 (R112, R158). Despite progress, it remains unclear how these small amino acid differences in apoE sequence among the three isoforms lead to profound effects on aging and disease-related pathways. Here, we propose a novel "ApoE Cascade Hypothesis" in AD and age-related cognitive decline, which states that the biochemical and biophysical properties of apoE impact a cascade of events at the cellular and systems levels, ultimately impacting aging-related pathogenic conditions including AD. As such, apoE-targeted therapeutic interventions are predicted to be more effective by addressing the biochemical phase of the cascade.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests G.B. consults for SciNeuro and Lexeo, has consulted for Vida Ventures, AbbVie, E-Scape, and Eisai, is on the scientific advisory board of Kisbee Therapeutics, and serves as a Co-Editor-in-Chief for Molecular Neurodegeneration. D.M.H. is as an inventor on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies. D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics. C2N Diagnostics has licensed certain anti-tau antibodies to AbbVie for therapeutic development. D.M.H. is on the scientific advisory board of Denali, Genentech, and Cajal Neurosciences and consults for Eli Lilly. D.M.H. receives sponsored research agreements to Washington University from NextCure, C2N Diagnostics, Yumanity, Eli Lilly, and Novartis. A.M.G. is on the scientific advisory board of Genentech and has consulted for Cognition Therapeutics and AbbVie. The other authors declare no competing interests.
Figures



References
-
- Arboleda-Velasquez JF, Lopera F, O'Hare M, Delgado-Tirado S, Marino C, Chmielewska N, Saez-Torres KL, Amarnani D, Schultz AP, Sperling RA, et al. (2019). Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nat Med 25, 1680–1683. 10.1038/s41591-019-0611-3. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous